Table 4.
Discrimination of different models in their ability to distinguish patients with a low risk of LNM.
| Model | Criteria for low risk of LNM | Proportion of low-risk group | Number of LNM in low-risk group | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|---|---|
| Model A (3) | Probability of LNM calculated by the nomogram <0.2 | 73.4% (384/523) | 18 (65 in total) | 72.3% * | 79.9% | 33.8% * | 95.3% |
| Model B (28) | Pathological grade 1; Myometrial invasion <1/2; Serum CA125 <35 IU/ml |
51.7% (89/172) * | 1 (18 in total) | 94.4% * | 57.1% * | 20.5% * | 98.9% |
| Model C (15) | Ratio of [(P53 + Ki67)/(ER + PR)] < 0.71 | 78.1% (375/480) | 28 (57 in total) | 50.9% * | 82.0% | 27.6% * | 92.5% * |
| Model D (11) | Serum CA125 < 30.0 IU/mL, PR > 50% and Ki67 < 40%. | 61.9% (229/370) * | 6 (39 in total) | 84.6% * | 67.4% * | 23.4% * | 97.3% |
| Model E (29) | Endometrioid histology; For FIGO stage IA grade 1 or 2: 1) ER ≥30%; 2) ER < 30% and PR ≥15%. For FIGO stage IA grade 3, or FIGO stage IB grade 1 or 2: 1) no LVSI; 2) LVSI and PR ≥15%; |
72.7% (346/476) | 15 (58 in total) | 74.1% * | 79.2% | 33.1% * | 95.7% |
| Model proposed in this study | Probability of LNM calculated by the nomogram <0.18 | 72.2% (393/544) in training cohort | 15 (87 in total) | 82.8% | 82.7% | 47.7% | 96.2% |
| 67.2% (156/232) in validation cohort | 2 (42 in total) | 95.2% | 80.2% | 52.6% | 98.7% |
NPV, negative predictive value; LVSI, lymphovascular space invasion; ER, estrogen receptor; PR, progesterone receptor. *P < 0.05 compared with the model proposed in this study.